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Evaluation of FoxP3 expression in peripheral T-cell lymphoma
Abstract
Peripheral T-cell lymphomas (PTCLs) are biologically heterogeneous and have not been successfully
correlated with specific T-cell subsets. We investigated PTCL, not otherwise specified (NOS),
angioimmunoblastic T-cell lymphoma (AILT), and anaplastic large cell lymphoma (ALCL) cases for
FoxP3 expression to determine a potential derivation from regulatory T (Treg) cells. One PTCL-NOS
case strongly expressed FoxP3 in the neoplastic T cells and showed unusual histomorphologic features
with a dense infiltration of the lymph node by immunoblastic T cells and almost no reactive background
infiltrate. The patient died shortly after diagnosis, suggesting that biologic properties of Treg cells may
have contributed to the rapidly fatal clinical course. All remaining PTCL-NOS and AILT cases showed
FoxP3 positivity only in the reactive infiltrate. Among ALCL cases, 4 of 6 ALK+ cases displayed weak
and inhomogeneous FoxP3 expression in the tumor cells. FoxP3+ PTCL-NOS presumably derived from
bona fide Treg cells occurs but seems rare in the Western population.
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A b s t r a c t
Peripheral T-cell lymphomas (PTCLs) are 
biologically heterogeneous and have not been 
successfully correlated with specific T-cell subsets. 
We investigated PTCL, not otherwise specified (NOS), 
angioimmunoblastic T-cell lymphoma (AILT), and 
anaplastic large cell lymphoma (ALCL) cases for 
FoxP3 expression to determine a potential derivation 
from regulatory T (Treg) cells. One PTCL-NOS case 
strongly expressed FoxP3 in the neoplastic T cells 
and showed unusual histomorphologic features with a 
dense infiltration of the lymph node by immunoblastic 
T cells and almost no reactive background infiltrate. 
The patient died shortly after diagnosis, suggesting that 
biologic properties of Treg cells may have contributed 
to the rapidly fatal clinical course. All remaining 
PTCL-NOS and AILT cases showed FoxP3 positivity 
only in the reactive infiltrate. Among ALCL cases, 4 
of 6 ALK+  cases displayed weak and inhomogeneous 
FoxP3 expression in the tumor cells. FoxP3+ 
PTCL-NOS presumably derived from bona fide Treg 
cells occurs but seems rare in the Western population.
The World Health Organization (WHO) classification of 
malignant lymphoma relies on the concept of normal B- and 
T-cell counterparts. Although this concept has been success-
fully established in many subsets of B-cell lymphomas, it 
has proven difficult to adopt this strategy in the less frequent 
T-cell lymphomas.1
By gene expression analyses, several subsets of effector 
T cells (T-helper 1, T-helper 2, and germinal center B-helper 
T cells), as well as memory subsets (central memory and 
effector memory), and cytotoxic T cells have been well 
defined on the molecular level.2 Immunologically, most of 
these T-cell subsets are characterized by their interleukin (IL) 
production or by defined responses to stimulatory mecha-
nisms. However, in tissue sections from routinely obtained 
and paraffin-embedded lymph node specimens, it is difficult 
to recognize these normal T-cell subsets because they have 
overlapping immunohistochemical features. In an attempt to 
relate T-cell lymphomas to their nonneoplastic counterpart, it 
was recently suggested that angioimmunoblastic T-cell lym-
phomas (AILTs) correlate with germinal center B-helper T 
cells based on their expression of CXCL13 and CD10.3,4
The idea of T cells that are able to regulate immune 
responses dates back to the 1970s when T cells were defined that 
were capable of inhibiting autoimmune reactions. Currently, 
such T cells are known as regulatory T (Treg) cells. Based on 
mouse models, Treg cells are characterized by the expression 
of CD4 and CD25 and by the secretion of important effector 
cytokines such as IL-10 and transforming growth factor β, 
that can be produced under certain circumstances.5 However, 
CD25– Treg cells also exist among humans and mice.
6-13 Treg 
cells constitutively express CD45RO,14 FAS,15 CTLA-4, and 
an αβ T-cell receptor (TCR),16 and, more recently, FoxP3 
614     Am J Clin Pathol  2008;130:613-619
614     DOI: 10.1309/L65GWEQ803PP6VX1    
© American Society for Clinical Pathology
Bonzheim et al / FoxP3 in PTCL
has been described as an important transcription factor that 
is essential for the differentiation of T cells into regulatory 
CD4+/CD25+ T cells.17 Lack of functional FoxP3 leads to a 
human autoimmune syndrome called IPEX (immunodysregu-
lation, polyendocrinopathy, enteropathy, X-linked).18 Besides 
natural Treg cells that express FoxP3 constitutively, so-called 
adaptive/induced Treg cells have been described that express 
FoxP3 only after induction.6-8,10,15,17,19,20 In solid tumors, the 
occurrence of Treg cells among tumor-infiltrating lymphocytes 
has been proposed to facilitate invasive growth by suppres-
sion of the immune responses.21,22
Given that FoxP3 is a crucial transcription factor that is 
specifically expressed in Treg cells,
23-25 we screened 83 periph-
eral T-cell lymphomas (PTCLs) for this marker to determine 
if Treg cells may represent the normal counterpart of a subset 
of PTCL. We identified 1 PTCL, not otherwise specified 
(NOS) with strong and uniform FoxP3 expression, suggesting 
that it may be derived from natural Treg cells. Furthermore, we 
demonstrated that FoxP3 is expressed in an inhomogeneous 
manner in ex vivo tissue of anaplastic lymphoma kinase 
(ALK)+ anaplastic large cell lymphoma (ALCL), pointing to 
an induced mode of FoxP3 expression as a consequence of 
ALK deregulation, in concert with recently published data of 
ALK+ ALCL cell lines expressing FoxP3.26
Materials and Methods
Immunohistochemical Analysis
We studied the expression of FoxP3 (rabbit polyclonal, 
dilution 1:50; Abcam, Cambridge, England) in lymph node 
specimens from 83 cases of PTCL by conventional immuno-
histochemical analysis. All cases had been diagnosed accord-
ing to the WHO classification and were characterized by 
using a broad panel of antibodies.
Of the study cases, 67 were paraffin-embedded material 
comprising 23 PTCL-NOS (9 of these were formerly diag-
nosed as T-immunoblastic non-Hodgkin lymphoma according 
to the Kiel classification), 16 AILT, 20 ALCL (14 ALK– and 6 
ALK+), and 8 other types of T-cell lymphoma (2 cutaneous, 4 
intestinal, 1 hepatosplenic, and 1 T/NK-cell lymphoma, nasal 
type). Because PTCLs contain numerous reactive T cells, 
we studied 16 frozen tumor samples from additional patients 
using double stains. These included 7 cases of AILT and 9 
cases of PTCL-NOS that have been reported previously.27
The 20 ALCL cases were further characterized for expres-
sion of CD4 (1F6, dilution 1:5; Loxo, Dossenheim, Germany), 
CD8 (C8/144B, dilution 1:20; DakoCytomation, Hamburg, 
Germany), CD30 (dilution 1:10; DakoCytomation), CD25 
(2A3, dilution 1:10; Becton Dickinson Immunocytometry 
Systems, San Jose, CA), CD45RO (ACT-1, dilution 1:500; 
DakoCytomation), FAS (B-10, dilution 1:250; Santa Cruz, 
Santa Cruz, CA), and CTLA-4 (BNI3, dilution 1:200; BD 
Biosciences, San Diego, CA).
Immunohistochemical analysis was performed according 
to standard protocols. Following deparaffinization, tissue sec-
tions were heat-treated for 6 minutes at 121°C using target-
retrieval solution, pH 6.1 (DakoCytomation) for the antibod-
ies CD25, FAS, CTLA-4, and FoxP3. For ALK1, CD4, CD8, 
CD45RO, and CD30 staining, heat treatment in citrate buffer, 
pH 6.0, was applied.
In the 7 AILT and 9 PTCL-NOS cases with available 
frozen material, we studied the expression of FoxP3 (goat 
polyclonal, dilution 1:200; Abcam), CD4 (MT310, dilution 
1:10; DakoCytomation), CD25 (ACT-1, dilution 1:2,000; 
DakoCytomation), CD45RO (UCHL1 FITC, dilution 1:10; 
Dianova, Hamburg, Germany), and FAS and CTLA-4 by 
fluorescence double stainings with the respective TCR Vβ 
antibody (Beckman Coulter, Marseille, France) recognizing 
the TCR Vβ segment that is rearranged and expressed by the 
neoplastic cells as previously shown.28 Fluorescence images 
were evaluated by using confocal laser scanning microscopy 
(Leica TCS2, Leica, Bensheim, Germany).
Statistical Analysis
We compared FoxP3 expression between ALK+ and 
ALK– ALCL cases by using the χ2 test. A P value less than 
.05 was considered statistically significant. Cluster analysis 
was performed to compare CD4, CD25, CD45RO, FAS, 
CTLA-4, and FoxP3 expression among ALCL cases.
Polymerase Chain Reaction for HTLV-1 Detection
The FoxP3+ PTCL-NOS was studied for a potential 
association with a human T-cell lymphotropic virus (HTLV)-1 
infection by a polymerase chain reaction (PCR) that detects the 
presence of proviral HTLV-1 DNA in the tumor. Primary and 
nested primers were used according to Costa et al.29 For this 
part of the study, 500 ng of DNA template, in a final volume 
of 25 µL, was amplified in a reaction mixture containing a final 
concentration of 0.2 µmol/L primer, 0.25 mmol/L deoxynucleo-
side triphosphates (Fermentas, St Leon-Rot, Germany), and 1× 
Taq polymerase buffer with 2 mmol/L of magnesium chloride 
and 0.65 U of Taq polymerase (Taq DNA polymerase, recom-
binant, Invitrogen, Karlsruhe, Germany). PCRs were run for 
35 cycles in a thermocycler (Mastercycler gradient, Eppendorf, 
Wesseling-Berzdorf, Germany). After a 5-minute denaturation 
at 94°C, each cycle consisted of 30 seconds at 94°C, 30 seconds 
at an annealing temperature of 60°C, and 1 minute 30 sec-
onds at 72°C followed by a final extension step of 7 minutes 
at 72°C. PCR products of the expected size were separated 
on an EtBr-stained agarose gel and purified (JETSORB gel 
extraction kit, Genomed, Loehne, Germany). Aliquots of 7 
µL were used for sequencing analysis with 1 µmol/L of the 
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respective primer and 2 µL of BigDye Terminator v3.1 Cycle 
Sequencing Reaction Mix (Applied Biosystems, Foster City, 
CA) in a final volume of 10 µL. Samples were analyzed in a 
3130xl Genetic Analyzer (Applied Biosystems).
Ethics Approval
Ethics approval for the entire study was obtained from the 
ethics committee, Medical Faculty, University of Würzburg, 
Würzburg, Germany. In general, the procedures followed the 
Helsinki Declaration of 1975. Informed patient consent was 
not required by the ethics committee because diagnostic speci-
mens can be used for research purposes after anonymization.
Results
AILT and Other Subtypes of PTCL
Among the 83 PTCL cases studied, the neoplastic T 
cells in all 23 AILT cases were completely FoxP3–. FoxP3 
positivity could only be detected in a few cells of the reac-
tive infiltrate (data not shown). Likewise, the neoplastic cells 
of the 8 cases belonging to other T-cell lymphoma subtypes 
(cutaneous, intestinal, and hepatosplenic T-cell lymphoma 
and T/NK-cell lymphoma, nasal type) were also completely 
negative for FoxP3 expression.
PTCL, Not Otherwise Specified
Among 14 PTCL-NOS cases primarily studied, only 1 
case strongly and uniformly expressed FoxP3. All remain-
ing 13 cases were negative. The results of the single stains 
in paraffin-embedded tissue were in agreement with those 
obtained in frozen specimens from 9 patients by fluorescence 
double staining and, thus, confirmed the presence of only a 
few FoxP3+ reactive T cells, whereas the neoplastic clone 
was FoxP3–.
Because the only case that showed strong FoxP3 expres-
sion in the neoplastic cells corresponded to the immunoblastic 
variant of PTCL-NOS (according to the Kiel classification), 
we studied 9 additional PTCL-NOS cases showing immuno-
blastic morphologic features. However, in all of these cases, 
the neoplastic cells were also negative for FoxP3.
Histologically, the FoxP3+ tumor showed a diffuse 
growth pattern of variably medium-sized or large atypi-
cal T cells with convoluted nuclei and mostly prominent 
nucleoli zImage 1Az. It is interesting that there was only a 
minor background infiltrate, which is rather unusual among 
PTCL cases zImage 1Bz. Immunohistochemically, the tumor 
cells expressed an αβ TCR (Vβ5s1) and CD4, CD45RO, 
FAS, and CTLA-4 zTable 1z and were negative for CD30 
(data not shown). In contrast, CD25 was undetectable on the 
immunohistochemical level. There was no evidence of an 
HTLV-1 association because HTLV-1 proviral DNA was not 
amplifiable by PCR. In contrast, a lymph node from a patient 
with known HTLV-1 infection that was used as a positive 
control sample displayed HTLV-1–specific PCR products as 
confirmed by sequence analysis (data not shown).
The FoxP3+ tumor occurred in a 59-year-old man 
with pathologically enlarged cervical, mediastinal, axillary, 
intra-abdominal, retroperitoneal, and inguinal lymph nodes 
who was diagnosed with a T-immunoblastic non-Hodgkin 
lymphoma according to the Kiel classification at that time, 
which falls into the category of PTCL-NOS in the current 
A B
zImage 1z A, FoxP3+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) (Giemsa, ×200). B, FoxP3+ PTCL-NOS 
(FoxP3/T-cell receptor Vβ fluorescence double staining [red, Vβ 5.1; blue, FoxP3; ×400]).
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WHO classification. At diagnosis, the patient was in a good 
physical condition and had stage IV disease, no evidence of 
involvement of extranodal sites, and an elevated lactate dehy-
drogenase value. He received chemotherapy according to the 
CHOEP (cyclophosphamide, doxorubicin, vincristine, etopo-
side, and prednisolone) protocol. Five days later, his general 
condition deteriorated and, during the chemotherapy-induced 
neutropenia phase, he had repeated infections. One month 
after the initial diagnosis, the patient died.
Anaplastic Large Cell Lymphoma
We studied FoxP3 expression in 20 lymph node speci-
mens from patients with ALCL, including ALK+ and ALK– 
tumors. We found expression of FoxP3 in 4 of 6 ALK+ ALCL 
and 1 of 14 ALK– ALCL cases. However, in contrast with the 
PTCL-NOS case described, FoxP3 expression was not strong 
and uniform, but rather relatively weak and variable among 
the tumor cells zImage 2z. On average, only 20% to 30% of 
the morphologically recognizable tumor cells were stained 
with FoxP3. The difference in FoxP3 expression between 
ALK1+ and ALK1– ALCL was statistically significant. In 
comparing the expression of other markers related to the Treg 
cell phenotype, which were, except CD25, also expressed in 
the FoxP3+ PTCL-NOS case (CD4, CD25, CD45RO, FAS, 
and CTLA-4) zTable 2z, we performed a cluster analysis of 
the immunohistochemical data obtained in the ALCL cases. 
zTable 1z 
Fluorescence Double Staining of a Marker Panel in Combination With an Antibody Directed Against the Respective T-Cell 
Receptor Vβ Segment Rearranged and Expressed by the Neoplastic T Cells in 7 Cases of AILT and 9 Cases of PTCL-NOS
Diagnosis FoxP3 CD4 CD25 CD45RO FAS CTLA-4
AILT – + – + + +
AILT – + – + + +
AILT – + (+) + + (+)
AILT – + – + + +
AILT – + (+) + + +
AILT – + – + + –
AILT – (+) (+) + + +
PTCL-NOS – + (+) + (+) (+)
PTCL-NOS – – – + + –
PTCL-NOS + + – + (+) (+)
PTCL-NOS – + (+) + + (+)
PTCL-NOS – + + + + –
PTCL-NOS – – – + + (+)
PTCL-NOS – + – + + –
PTCL-NOS – + + + + (+)
PTCL-NOS – – + – + –
AILT, angioimmunoblastic T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; +, positive; –, negative; (+), weak positivity.
A B
zImage 2z A, Anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL) (Giemsa, ×200). B, ALK+ ALCL (FoxP3 
staining, ×200).
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In contrast with the homogeneous staining pattern of FoxP3, 
FAS, and CTLA-4, a heterogeneous staining pattern was 
detected for CD4, CD25, and CD45RO among ALK+ and 
ALK– ALCL cases, indicating that ALCLs do not show 
the complete phenotype of Treg cells. Among the 11 CD4– 
ALCLs (Table 2), only 1 ALK+  ALCL (FoxP3–) expressed 
CD8 (data not shown).
Discussion
In this study, we tried to identify nodal PTCLs that may 
be derived from Treg cells. Surprisingly, we found only 1 
FoxP3+ PTCL-NOS among 63 PTCL cases, excluding ALCL 
cases. To the best of our knowledge, Treg cell phenotypes have 
not been described in nodal PTCL in Western countries. We 
therefore conclude that the derivation of nodal PTCL from 
Treg cells occurs but is a rare event, at least within the white 
population.
It is tempting to speculate that some of the morpho-
logic and clinical features of the case described herein may 
be explained by the retained regulatory function of the tumor 
cells. First, the tumor showed a growth pattern that is rare in 
PTCL-NOS because only a few tumor-infiltrating reactive T 
or B cells could be observed within the tumor cell infiltrate, 
and the growth pattern was almost cohesive. This paucity of 
reactive background cells may be caused by the immunosup-
pressive function of the tumor cells. Second, the regulatory 
T-cell function might have significantly suppressed antitu-
moral immunity, thereby contributing to the rapid progression 
of disease and poor clinical course of the patient. Although 
the majority of patients with PTCL-NOS have a poor clinical 
outcome, the rapid and fatal progression seen in the FoxP3+ 
case described herein differs from the typical clinical course 
of PTCL-NOS in general. Thus, FoxP3-expression and the 
associated regulatory phenotype might be an adverse biologic 
and clinical factor in rare PTCL cases that contributes to the 
aggressiveness of the tumor.
Particularly, the strong FoxP3 expression in our case 
suggests that this tumor might have arisen from a natural Treg 
cell, even though the tumor cells were negative for CD25, 
which is a phenotype that has been described among Treg cells 
in humans and mice.6-13 A subgroup of CCR4+ PTCL-NOS 
was previously associated with Treg cells by a Japanese group 
because these tumor samples expressed FoxP3 at elevated 
levels as measured by quantitative real-time PCR. However, 
this study did not investigate whether FoxP3 was coexpressed 
in the tumor cells or derived from accompanying nonneoplas-
tic Treg cells in the reactive infiltrate.
30 Whereas a Treg cell 
phenotype has not been convincingly demonstrated in nodal 
PTCL, subsets of extranodal PTCL have been suggested 
to be derived from Treg cells. In 5 studies, cases of HTLV-
1–associated adult T-cell leukemia/lymphoma (ATLL) have 
been shown to express FoxP3 and were, therefore, considered 
to be derived from Treg cells.
31-35 It is interesting that these 
lymphomas are also characterized by a poor prognosis.1,36,37 
Whereas purified tumor cells from peripheral blood mononu-
clear cells (PBMCs) or lymph nodes of patients with ATLL 
show in 50% to 100% of cases elevated FoxP3 expression by 
real-time PCR and immunohistochemical analysis, 1 study 
revealed widely varying results in Western blot analysis.33 
In addition to ATLL, 1 of 3 cases of T-cell prolymphocytic 
zTable 2z
Expression of a Marker Panel in 20 Cases of Anaplastic Large Cell Lymphoma
Case No. ALK1 FoxP3 CD4 CD25 CD45RO FAS CTLA-4
1 – – + – (+) + –
3 – – – + (+) + –
4 – – + – (+) + –
5 – – – + (+) + –
6 – – – – + + –
8 – – + + + + –
10 – – + + + + –
11 – – (+) + (+) + –
12 – – – – (+) + –
14 – – – – + + –
15 – – – + (+) + –
17 – – (+) – + + –
18 – (+) + + + + –
19 – – – + + + –
2 + – – + + (+) –
7 + – + + (+) (+) –
9 + (+) – – (+) + –
13 + (+) + + (+) + –
16 + (+) – + + + –
20 + (+) – + (+) (+) –
+, positive; –, negative; (+), weak positivity.
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leukemia showed evidence of FoxP3 expression in PBMCs 
studied by real-time PCR.34 Several studies suggest that FoxP3 
expression may be induced in CD4+ T cells under certain 
circumstances. For example, Walsh et al38 demonstrated that 
FoxP3 expression and an associated regulatory phenotype 
correlated with retroviral HTLV-1 infection in cultured CD4+ 
T cells. Conversely, however, increased levels of FoxP3 were 
also found in PBMCs of 3 of 12 HTLV– cutaneous T-cell lym-
phomas by quantitative real-time PCR.38 This finding may be 
explained by the finding of Berger and colleagues,39 who were 
able to demonstrate that a regulatory T-cell phenotype can be 
induced in cutaneous T-cell lymphoma by cultivating purified 
PBMCs with dendritic cells loaded with apoptotic material. In 
our case, we demonstrated by PCR that the regulatory pheno-
type was not associated with an HTLV-1 infection.
In contrast with the aforementioned entities, the mode of 
FoxP3 induction in ALK+ ALCL seems to be different. Only 
a subset of tumor cells in ALK+ ALCL expressed FoxP3, and 
the level of expression varied among tumor cells, pointing 
to an intricate mechanism of FoxP3 regulation. Recent data 
suggest that FoxP3 may be up-regulated as a consequence 
of ALK deregulation in ALCL, as has been shown in ALK+ 
ALCL cell lines. In particular, Kasprzycka et al26 demon-
strated elevated FoxP3 expression in 4 of 4 ALK+ ALCL cell 
lines as evidenced by real-time quantitative PCR, whereas by 
Western blot analysis, 1 of the cell lines showed strong and 3 
showed weak FoxP3 expression. The same authors provided 
evidence that the regulatory T-cell phenotype was induced by 
ALK, as lymphoid cells transfected with NPM/ALK induced 
the Treg cell phenotype, and inhibition of NPM/ALK func-
tion in ALK+ cell lines suppressed the Treg cell phenotype. 
Furthermore, the authors identified STAT3, which is acti-
vated by NPM/ALK, as an effector of the Treg cell phenotype 
induction by activating IL-10, transforming growth factor β, 
and FoxP3 expression. In line with these results, we found 
significantly different FoxP3 expression between ALK+ and 
ALK– ALCLs. Only 1 of 14 ALK− ALCLs expressed FoxP3. 
Considering these findings together, the induced FoxP3 
expression in ALK+ ALCLs seems to be an epiphenomenon 
following aberrant ALK overexpression without a real Treg 
cell derivation of the tumor cells. This conclusion may be 
additionally supported by our results that show a lack of other 
characteristics of Treg cells, as CD4, CD25, CD45RO, FAS, 
and, especially, CTLA-4 are not constantly coexpressed with 
FoxP3 (Table 2).
We describe a putatively natural Treg cell phenotype in 
a case of a nodal PTCL-NOS. Some of the morphologic and 
clinical peculiarities of this case may be explained by the 
retained Treg cell function in the neoplastic T-cell clone. Thus, 
although rare, a Treg cell phenotype may represent an adverse 
risk factor in PTCL-NOS.
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